Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer
Authors:
- Eva CiruelosECEva Ciruelos
- Christian JackischCJChristian Jackisch
- 9 February 2014
- journal article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 14 (5) , 511-521
Abstract
Nab-paclitaxel (Abraxane(®)) is an albumin-bound form of paclitaxel that utilizes the natural properties of albumin to improve paclitaxel delivery to the tumor. It is licensed for use in metastatic breast cancer (MBC) at a dose of 260 mg/m(2) Q3W based on its superior therapeutic index versus conventional paclitaxel 175 mg/m(2) Q3W demonstrated in a Phase III study. In a post-hoc analysis, nab-paclitaxel treatment was associated with rapid and dramatic tumor responses in patients with poor prognostic factors (visceral dominant disease, ≥3 metastatic lesions), suggesting it may be a preferred treatment for these patients. Moreover, significant efficacy has been seen with nab-paclitaxel 100 and 150 mg/m(2) QW 3/4, suggesting it may be possible to tailor use of this agent in the future.Keywords
This publication has 56 references indexed in Scilit:
- Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimenBreast Cancer Research and Treatment, 2012
- Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2012
- Weeklynab-Paclitaxel in Metastatic Breast Cancer – Summary and Results of an Expert Panel DiscussionBreast Care, 2012
- Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: A clinical reviewThe Breast, 2011
- Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot studyBreast Cancer Research and Treatment, 2010
- A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancerBreast Cancer Research and Treatment, 2010
- Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancerBreast Cancer Research and Treatment, 2010
- Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531)Annals of Oncology, 2008
- Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel andnab-PaclitaxelClinical Cancer Research, 2008
- A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancerBreast Cancer Research and Treatment, 2008